Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Kare Chemical Technologies is a pharmaceutical technology company using a patented catalytic process to convert limonene, a citrus by-product, into high-purity CB1 and CB2 receptor ligands for drug development. It develops non-psychoactive therapeutic candidates aimed at safer alternatives to opioids and next-generation metabolic therapies.
2 investors
Karis Bio develops therapies based on human induced pluripotent stem cells (hiPSCs) to treat cardiovascular diseases, with initial focus on peripheral arterial disease and critical limb ischemia. The company targets vasculogenesis-related conditions such as ischemic heart disease, diabetic retinopathy, diabetic neuropathy, and wound healing.
2 investors
Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers. Its work centers on inhibiting the MDM2-p53 interaction as a therapeutic target in oncology.
2 investors
Karyosoft is a no-code genomics platform for secondary and tertiary NGS analytics, designed for agricultural biotechnology researchers, universities, and bioinformatics teams. It enables scientists to analyze genomic datasets without coding expertise while maintaining data security and standardizing research workflows.
2 investors
Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
2 investors
KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs. It uses an integrated discovery and development platform, including a pharmacology experimental platform, to advance differentiated drug candidates from bench to clinic.
2 investors
A biopharmaceutical company developing targeted cancer drugs and related therapies. The company focuses on drug discovery, clinical development, and commercialization to address unmet oncology needs in China and globally.
2 investors
Kelonia is a biotechnology company developing next-generation genetic medicines, with a focus on cell and gene therapy programs including in vivo approaches and oncology applications. It advances therapeutic programs from preclinical research through clinical development.
2 investors
KelSie Biotech is a biotechnology company developing and commercializing drug-delivery technologies licensed from Sievers Biotech, including a Bubble Drying Process, sublingual wafers, and dry powder inhalable products. The company holds worldwide rights to formulate, sell, and sublicense finished products based on this technology and intellectual property.
2 investors
Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
2 investors
2 investors
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-Ξ²) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart. Its pipeline targets neuromuscular diseases and ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.
2 investors
Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. It operates in the biopharmaceutical and therapeutics sector.
2 investors
Kimia develops a drug discovery platform called ATLAS that combines active learning, automated chemical synthesis, high-throughput screening, and machine learning to design and optimize novel drug molecules. The company generates large-scale chemical and biological datasets to map the relationship between chemical structure and protein function for generative drug design.
2 investors
Kind Biotechnology develops the ION platform, which uses artificial genomic constructs to grow interconnected peripheral organs for xenotransplantation. The company aims to address organ scarcity in transplant medicine to treat age-related organ failure and extend healthy human lifespan.
2 investors
Kiniciti is a platform company that operates cell and gene therapy-focused life science businesses, including Cellistic for iPSC-based manufacturing technologies and Ncardia for human iPSC products and drug discovery services. The company serves therapeutic developers and pharmaceutical companies seeking scalable cell therapy manufacturing and drug discovery solutions.
2 investors
2 investors
KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases. Its platform combines proprietary multi-species single domain antibody transgenic mice, AI-enabled antibody fingerprinting, and multi-specific antibody engineering for therapeutic, diagnostic, and vaccine development.
2 investors
Kite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
2 investors
Kivo is a document management system for life sciences organizations that ensures GxP compliance through 21 CFR Part 11 e-signatures, access controls, and audit trails. The platform integrates DocuSign and Microsoft Office to support collaborative authoring, approval workflows, training assignments, and real-time compliance reporting.
2 investors
KIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.
2 investors
Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.
2 investors
KOA Biotech develops early pathogen detection technology for aquaculture to reduce fish mortality and antibiotic use. The company serves aquaculturists seeking to improve productivity and sustainability in fish farming.
2 investors
Kometa Bio develops dental surgical devices, specifically the Smart Dentin Grinder, which processes autologous dentin for bone augmentation procedures in dental practice.
2 investors